New schizophrenia shot could replace daily pills

NCT ID NCT06315283

Completed Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new long-acting olanzapine injection (TV-44749) against the standard oral olanzapine pill in 153 people with schizophrenia. The goal was to see if the shot delivers similar drug levels and is safe. Participants received multiple doses over 21 weeks, with researchers measuring how well the body absorbs the drug and tracking side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Teva Investigational Site 15737

Marlton, New Jersey, 08053, United States
Teva Investigational Site 15738

Hollywood, Florida, 33024, United States
Teva Investigational Site 15739

Los Alamitos, California, 90720, United States
Teva Investigational Site 15740

Torrance, California, 90504, United States
Teva Investigational Site 15741

Atlanta, Georgia, 30331, United States
Teva Investigational Site 15742

Decatur, Georgia, 30030, United States
Teva Investigational Site 31326

Zamora, 49021, Spain
Teva Investigational Site 34310

Surrey, KT22 7AD, United Kingdom
Teva Investigational Site 60053

Zagreb, 10090, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.